$VSTM if you're investing here this is the time to cost average. Two Data readouts this quarter & several recent price target upgrades. One of these read outs has a Breakthrough Therapy Designation and could see expedited approval. They have plenty of cash and catalysts for the 2H 22'. This is a value play, beat down on nothing but lack of interest and a bad market environment. Not to mention, success in one of these trials will yield more optimism for the rest of the pipeline. The data in LGSOC is quite solid. Cost average, be willing to weather pain and this could be a 4-5x.
2
3
3 Likes